Frequently asked questions
In 2022, the ELISA Testing market was estimated to be worth USD 2154.8 million.
The ELISA Testing market is anticipated to increase at a CAGR of 7.20% from 2023 to 2030, reaching USD 3758.07 million in 2030.
Regarding application, the cancer category is the largest.
The sector leader with regard to the test type is direct ELISA.
During the forecast period, the research institutes segment is anticipated to have the greatest CAGR.
The ELISA Testing market was controlled by North America.
The top players include Danaher Corporation, Quidel Corporation, Ortho Clinical Diagnostics, BioMérieux SA, Bio-Rad Laboratories, Abbott Laboratories, F. Hoffmann-La Roche AG, Sysmex Corporation, Thermo Fisher Scientific, Inc., Siemens Healthineers, and others.
The market for ELISA Testing is expanding due to several factors, including the move towards personalized treatment, improvements in ELISA technology, the ability to detect cancer biomarkers, and awareness and preventive initiatives.
Higher testing prices, complexity, labor-intensiveness, a lack of standardization, the advent of substitute technologies, and cost containment in healthcare are the factors restraining the expansion of the ELISA Testing market.
The important market prospects contain the persistent demand for diagnostic tests, including ELISA assays for infectious diseases, the use of ELISA assays in food safety investigation, and the use of ELISA-based assays in veterinary medicine to diagnose infectious diseases in animals.